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nhancing Stem Cell Therapy
hrough Genetic Modification*
ictor J. Dzau, MD,
assimiliano Gnecchi, MD,
lok S. Pachori, PHD
urham, North Carolina
ecent promising experimental results have suggested the
ossibility of regenerating damaged myocardium using adult
one marrow-derived stem cells (1–4). The biologic phe-
omenon of tissue regeneration and its potential clinical
pplication have captivated the enthusiasm of scientists and
linicians alike. However, the field of stem cell research is
till in its infancy, and to date stem cell therapy has been
ampered by many unaddressed biologic and technical
roblems. A complete understanding of the ideal approach
n terms of choice of cell type, time, and method of delivery
ay take years of investigation.
See page 1339
Several different populations of stem cells have been
hown to reduce ventricular remodeling and increase cardiac
unction when injected into infarcted hearts in experimental
odels. However, much controversy exists over the cellular
echanisms by which such structural and functional recov-
ries are achieved (5,6). For example, the ability of hema-
opoietic stem cells to transdifferentiate (1) into cardio-
yocytes has been challenged (7–9), generating an intense
ebate over fusion versus transdifferentiation (10). There is
eneral agreement that the endothelial progenitor cells have
he capacity to induce neo-angiogenesis that may second-
rily influence remodeling and function (11,12). It has also
een reported that adult bone-marrow-derived mesenchy-
al stem cells (MSCs) may differentiate into cardiac myo-
ytes and hence provide an alternative population for cell
herapy of the damaged myocardium. However, to date the
ethod of isolation and time required to expand and obtain
ufficient numbers of MSCs make this cell population less
han ideal for clinical application. On the other hand, from
biologic point of view, the MSCs are interesting cells
iven their multipotency and immunomodulatory proper-
ies. Mesenchymal stem cells are probably more suitable for
ardiac cell therapy because it has been reported that they
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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raining Grant HL 69601-01.ave the ability to differentiate into cardiomyocytes without
rossing developmental barriers (13–16).
A major limitation to the efficacy of cell therapy is the poor
iability of the transplanted cells. Indeed, the functional im-
rovement from stem cell therapy has been quite modest.
enetic modification of stem or progenitor cells may represent
n important strategic advancement in regenerative medicine.
y combining gene with cell therapy, one may be able to
nhance stem cell function and viability. Indeed, genetic
odification can improve survival, metabolic characteristics,
ontractility, proliferative capacity, or differentiation of the
tem cells. Furthermore, the cells may become a vehicle for
ene therapy whose secreted gene products can exert paracrine
r endocrine actions that may result in further therapeutic
enefits. Our group was the first to conceptualize this approach
nd showed that MSCs overexpressing the anti-apoptotic gene
kt1 (Akt-MSCs) became more resistant to apoptosis in vitro
nd in vivo (17). Furthermore, when injected into infarcted
earts, Akt-MSCs dramatically limit ventricular remodeling
nd improve cardiac function.
The salutary effects of this approach are further validated
nd extended in the study by Tang et al. (18) published in
his issue of the Journal. The main finding of this study is
hat a higher number of MSCs transduced with heme
xygenase (HO)-1 survive when they are injected into
nfarcted hearts, leading to more efficient healing compared
ith control MSCs. Of interest is the fact that HO-1 is
nown to have cardioprotective properties, and thus its
aracrine actions may also have contributed to the thera-
eutic effects observed by Tang et al. (18). This study
rovides further proof of the concept that an ideal combi-
ation of cell and gene therapy might represent a future
magic bullet” for myocardial repair and regeneration.
In their study, Tang et al. (18) used HO as the gene to
odify the MSCs for cardiac cell therapy. Heme oxygenase is
n enzyme whose antioxidant function depends on its ability to
revent heme from causing oxidative damage. A major focus of
O’s biologic effects has also been on the role of by-products
f heme catabolism (carbon monoxide, bilirubin, and iron) that
ave been demonstrated to have anti-inflammatory, anti-
poptotic, anti-mitogenic, and vasodilator effects (19). Emerg-
ng evidence provides strong support for a protective role of
O-1 in the cardiovascular system. The HO-1 expression
nhibits growth of vascular smooth muscle cells and protects
gainst injury induced vascular neointima formation in vivo
20–23). Yet et al. (24) have recently demonstrated that
ardiac-specific overexpression of HO-1 protects against isch-
mia/reperfusion injury. However, constitutive high-level ex-
ression of HO has also been associated with cytotoxic effects
25,26). To avoid this potential problem in HO-1 gene
herapy, we have proposed that inducible and regulated expres-
ion of HO-1 may provide a superior strategy. Toward that
oal, we have demonstrated that hypoxia-inducible expression
f HO-1 protects tissues against acute ischemia/reperfusion
njury and reduces cell death (27). The study by Tang et al. (18)
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Editorial Comment October 4, 2005:1351–3xtends our observation and provides evidence for the anti-
poptotic role of HO-1 in stem cell therapy. However, it is not
lear whether the myocardial protective effect is due to direct
ffects of HO-1, or its soluble by-products acting intracellularly
r in a paracrine manner on ischemic/injured cardiomyocytes,
r both. Nonetheless, the data in the study support the
rotective role of HO-1 and confirm our prior observation on
he superior efficacy of genetically modified stem cells for
ardioprotection.
There is a growing body of evidence supporting the
ypothesis that paracrine mechanisms mediated by factors
eleased by the MSCs play an essential role in the reparative
rocess observed after their injection into infarcted hearts,
n addition to the direct regenerative potential of the MSCs.
ndeed, it has been reported that the release of paracrine
rowth factors from MSCs can promote neo-angiogenesis
28). We have recently demonstrated that conditioned
edium from Akt-MSCs contains soluble factors able to
rotect ischemic cardiomyocytes from cell death both in
itro and in vivo (29). From this perspective, the genetic
anipulation of stem cells could open unexpected research
nd clinical horizons. Thought as a strategy to increase cell
iability, the overexpression of Akt turns out to have many
ore effects on MSCs such as the production of secreted
actors capable of protecting adult rat cardiomyocytes both
n vitro and in vivo. Thus, Akt-MSCs reveal themselves as
new model to identify possible novel cyto-protective
actors eventually suitable for myocardial ischemia therapy.
n the basis of the data of Tang et al. (18), the beneficial
ffects obtained with the MSCHO-1 appeared also to be
rimarily due to paracrine protective action, even though
his hypothesis was not directly addressed in the present
tudy. Indeed, the low differentiation rate of MSC to
ardiomyocyte suggested by the authors could not alone
xplain the structural and functional improvements re-
orted. Thus, as in the case of the Akt-MSCs, the original
ntervention, intended to increase stem cell viability, might
ave induced paracrine effects on adjacent myocardium.
ertainly, it would have been interesting if Tang et al. (18)
ad tested this hypothesis and also had determined whether
he overexpression of HO-1 could modify the expression of
ther secreted factors by the MSCs.
We believe that, besides cardiac regeneration by donor
ells, either through fusion or differentiation, the paracrine
echanism plays an important role in cardiac repair after
dult stem cell transplantation. In addition to the pro-
ngiogenic and anti-apoptotic effects, we anticipate that
tem cells can exert other paracrine effects such as increase in
ardiac contractility, improvement of cardiac metabolism,
nd enhancement of regeneration by resident cardiac pro-
enitor cells. Cardiac stem cell therapy holds promise in the
uture treatment of heart disease such as acute myocardial
nfarction, chronic ischemic heart disease, and congestive
eart failure. The therapy’s current use is significantly
ampered by biologic and technologic challenges. Genetic
odification of stem cells as described by us previously (17)
1nd now by Tang et al. (18) represents an important advance-
ent because this approach may overcome the issue of cell
iability, scalability, and immune tolerance. Furthermore, the
unctions of the stem cells may be further enhanced by their
enetic manipulation. Finally, the recent demonstration that
enetically modified cells may secrete therapeutic factors pro-
ides a potential breakthrough in that, rather than administer-
ng cells, one may be able to administer specific proteins
roduced by these cells for cardiac therapy (29).
eprint requests and correspondence: Dr. Victor J. Dzau, Office
f the Chancellor, Duke University Medical Center, P.O. Box
701 Medical Center, Durham, North Carolina 27708. E-mail:
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